| abstract |
The present invention relates to the use of a calcium salt composition to reduce the absorption of a pathogen, while the use involves administering to an individual in need an effective amount of a calcium salt composition sufficient to increase the surface viscoelasticity of the air-liquid interface of the mucous layer at the injection site, while pathogen decreases. In particular, the present invention relates to the use of a calcium salt formulation, wherein said pathogen causes a respiratory disease or a pulmonary infection. |